Targeting the power of glycomics to improve the treatment of mucosal and dermal diseases.

Introducing an innovative Glycomics Technology Platform that has lead to the development of breakthrough therapeutics that improve pulmonary, gastrointestinal, oral, ophthalmic, wound, and sinus health. By targeting complex cell surface and mucosal interactions, we produce formulations with the ability to control inflammation and infection to promote healing.  See Pipeline

See our lead programs
Learn how our therapeutics work
Partner with us to develop and scale breakthrough therapeutics

Synedgen uses the science of glycomics – the study of complex sugar structure and function – to discover and develop ultra-purified therapeutic polysaccharides that are soluble, active, and targeted in the human body.  Our new molecular entities are designed to alter the progression of diseases and improve the lives of patients.

Our unique, proprietary glycomics platform

The Synedgen glycomics development engine provides a clear competitive advantage. Our technology platform, based on powerful and validated science, creates limitless product opportunities at mucosal and dermal systems where pathogens, external contaminants and injury disrupt natural innate immune defenses. Our glycomics technologies show unprecedented safety profiles in preclinical studies. Synedgen’s glycomics technologies mediate inflammation, control infection, and promote healing at the dermal and mucosal interface.

Improving lives by changing the progression of disease

News

October 10, 2018

Synedgen Announces the Launch of Moisyn Rinse to Treat Dry Mouth
Read More

September 19, 2018

Synedgen Appoints Kaveri Parker, Ph.D. as Chief Business Officer
Read More

May 23, 2018

Synedgen Receives FDA 510(k) Clearance for Catasyn™ Advanced Technology Wound Hydrogel
Read More